Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 4543861, 10 pages
http://dx.doi.org/10.1155/2016/4543861
Review Article

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis

1Guangzhou Hospital of Guangzhou Military Region, Guangzhou, China
2School of Public Health, Guangzhou Medical University, Guangzhou, China
3Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Received 11 March 2016; Revised 28 August 2016; Accepted 18 September 2016

Academic Editor: Leandro J. Carreño

Copyright © 2016 Renliang Yi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, Programmes and projects: Cancer, http://www.who.int/cancer/en/.
  2. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent et al., “Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012,” European Journal of Cancer, vol. 49, no. 6, pp. 1374–1403, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. G. L. Plosker, “Sipuleucel-T: in metastatic castration-resistant prostate cancer,” Drugs, vol. 71, no. 1, pp. 101–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. Ö. Acar, T. Esen, and N. A. Lack, “New therapeutics to treat castrate-resistant prostate cancer,” The Scientific World Journal, vol. 2013, Article ID 379641, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. S. M. Geary, C. D. Lemke, D. M. Lubaroff, and A. K. Salem, “Proposed mechanisms of action for prostate cancer vaccines,” Nature Reviews Urology, vol. 10, no. 3, pp. 149–160, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. C. R. Pound, A. W. Partin, M. A. Eisenberger, D. W. Chan, J. D. Pearson, and P. C. Walsh, “Natural history of progression after PSA elevation following radical prostatectomy,” Journal of the American Medical Association, vol. 281, no. 17, pp. 1591–1597, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. D. L. Suzman and E. S. Antonarakis, “Castration-resistant prostate cancer: latest evidence and therapeutic implications,” Therapeutic Advances in Medical Oncology, vol. 6, no. 4, pp. 167–179, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Petrioli, E. Francini, and G. Roviello, “Is there still a place for docetaxel rechallenge in prostate cancer?” World Journal of Clinical Oncology, vol. 6, no. 5, pp. 99–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Badrising, V. van der Noort, I. M. van Oort et al., “Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment,” Cancer, vol. 120, no. 7, pp. 968–975, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. C.-H. Ohlmann, “Chemotherapy of prostate cancer,” Urologe, vol. 54, no. 10, pp. 1461–1470, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Printz, “New prostate cancer drugs hold promise,” Cancer, vol. 119, no. 2, pp. 247–248, 2013. View at Publisher · View at Google Scholar
  13. D. Lorente, J. Mateo, R. Perez-Lopez, J. S. de Bono, and G. Attard, “Sequencing of agents in castration-resistant prostate cancer,” The Lancet Oncology, vol. 16, no. 6, pp. e279–e292, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. R. M. Bambury and D. E. Rathkopf, “Novel and next-generation androgen receptor–directed therapies for prostate cancer: beyond abiraterone and enzalutamide,” Urologic Oncology: Seminars and Original Investigations, vol. 34, no. 8, pp. 348–355, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. L. T. Dauer, M. J. Williamson, J. Humm et al., “Radiation safety considerations for the use of 223RaCl2 de in men with castration-resistant prostate cancer,” Health Physics, vol. 106, no. 4, pp. 494–504, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Iacovelli, A. Palazzo, G. Procopio, P. Gazzaniga, and E. Cortesi, “Abiraterone acetate in castration-resistant prostate cancer,” Anti-Cancer Drugs, vol. 23, no. 3, pp. 247–254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Bhattacharya, M. Hirmand, D. Phung, and S. van Os, “Development of enzalutamide for metastatic castration-resistant prostate cancer,” Annals of the New York Academy of Sciences, vol. 1358, no. 1, pp. 13–27, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Lebdai, V. Basset, J. Branchereau et al., “What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?” World Journal of Urology, vol. 34, no. 5, pp. 617–624, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Parker, S. Nilsson D Heinrich, S. I. Helle et al., “Alpha emitter radium-223 and survival in metastatic prostate cancer,” New England Journal of Medicine, vol. 369, no. 3, pp. 213–223, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. P. W. Kantoff, T. J. Schuetz, B. A. Blumenstein et al., “Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1099–1105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. P. G. Kluetz, Y.-M. Ning, V. E. Maher et al., “Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. food and drug administration drug approval summary,” Clinical Cancer Research, vol. 19, no. 24, pp. 6650–6656, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. M. Ning, W. Pierce, V. E. Maher et al., “Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. foodand drugadministrationdrug approval summary,” Clinical Cancer Research, vol. 19, no. 22, pp. 6067–6073, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Cheever and C. S. Higano, “PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine,” Clinical Cancer Research, vol. 17, no. 11, pp. 3520–3526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Kim and C. J. Ryan, “Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies,” Cancer, vol. 121, no. 3, pp. 361–371, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. B. A. Gartrell and F. Saad, “Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy,” Therapeutic Advances in Urology, vol. 7, no. 4, pp. 194–202, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. J. B. Aragon-Ching, “Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer,” Asian Journal of Andrology, vol. 16, no. 6, pp. 803–804, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. P. A. Burch, J. K. Breen, J. C. Buckner et al., “Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer,” Clinical Cancer Research, vol. 6, no. 6, pp. 2175–2182, 2000. View at Google Scholar · View at Scopus
  28. C. J. Paller and E. S. Antonarakis, “Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges,” Human Vaccines & Immunotherapeutics, vol. 8, no. 4, pp. 509–519, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. E. J. Small, P. F. Schellhammer, C. S. Higano et al., “Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3089–3094, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. G. A. Wells, B. Shea, D. O'Connell et al., “The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses,” http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
  31. C. S. Higano, P. F. Schellhammer, E. J. Small et al., “Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer,” Cancer, vol. 115, no. 16, pp. 3670–3679, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. P. W. Kantoff, C. S. Higano, N. D. Shore et al., “Sipuleucel-T immunotherapy for castration-resistant prostate cancer,” The New England Journal of Medicine, vol. 363, no. 5, pp. 411–422, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Fizazi, H. I. Scher, A. Molina et al., “Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study,” The Lancet Oncology, vol. 13, no. 10, pp. 983–992, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. D. E. Rathkopf, M. R. Smith, J. S. De Bono et al., “Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302),” European Urology, vol. 66, no. 5, pp. 815–825, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. H. I. Scher, K. Fizazi, F. Saad et al., “Increased survival with enzalutamide in prostate cancer after chemotherapy,” The New England Journal of Medicine, vol. 367, no. 13, pp. 1187–1197, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. T. M. Beer and B. Tombal, “Enzalutamide in metastatic prostate cancer before chemotherapy,” The New England Journal of Medicine, vol. 371, no. 18, pp. 1755–1756, 2014. View at Publisher · View at Google Scholar
  37. H. Lim, K. M. Kim, S. Jeong, E. K. Choi, and J. Jung, “Chrysin increases the therapeutic efficacy of docetaxel and mitigates docetaxel-induced edema,” Integrative Cancer Therapies, 2016. View at Publisher · View at Google Scholar
  38. T. Zhou, S.-X. Zeng, D.-W. Ye et al., “A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer,” PLoS ONE, vol. 10, no. 1, Article ID e0117002, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Agarwal, G. Di Lorenzo, G. Sonpavde, and J. Bellmunt, “New agents for prostate cancer,” Annals of Oncology, vol. 25, no. 9, Article ID mdu038, pp. 1700–1709, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Anassi and U. A. Ndefo, “Sipuleucel-T (Provenge) injection the first immunotherapy agent (Vaccine) for hormone-refractory prostate cancer,” P and T, vol. 36, no. 4, pp. 197–202, 2011. View at Google Scholar · View at Scopus
  41. C. G. Drake, “Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer,” Journal of the National Cancer Institute, vol. 104, no. 18, p. 1422, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. E. J. Small, R. S. Lance, T. A. Gardner et al., “A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer,” Clinical Cancer Research, vol. 21, no. 17, pp. 3862–3869, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Mohler, A. Armstrong, R. Bahnson et al., NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, V.4, 2013, https://www.nccn.org/.
  44. S. Badrising, V. Van Der Noort, I. M. Van Oort et al., “Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment,” Cancer, vol. 120, no. 7, pp. 968–975, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Loriot, D. Bianchini, E. Ileana et al., “Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100),” Annals of Oncology, vol. 24, no. 7, pp. 1807–1812, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. K. L. Noonan, S. North, R. L. Bitting, A. J. Armstrong, S. L. Ellard, and K. N. Chi, “Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide,” Annals of Oncology, vol. 24, no. 7, pp. 1802–1807, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. A. A. Azad, B. J. Eigl, R. N. Murray, C. Kollmannsberger, and K. N. Chi, “Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients,” European Urology, vol. 67, no. 1, pp. 23–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. A. J. Schrader, M. Boegemann, C.-H. Ohlmann et al., “Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone,” European Urology, vol. 65, no. 1, pp. 30–36, 2014. View at Publisher · View at Google Scholar · View at Scopus